By: Vicki Moore
A study reported in Blood Cancer Journal identified multiple factors associated with disparities in the time to treatment with oral antimyeloma medications. “We found considerable discrepancies between the timing of any treatment initiation and oral antimyeloma medication fill,” the researchers conducting the analysis wrote in their report.